In a report issued on May 4, Danielle Antalffy from SVB Securities reiterated a Buy rating on Vericel (VCEL – Research Report), with a price target of $45.00. The company’s shares closed last Friday at $26.90, close to its 52-week low of $26.49.
According to TipRanks.com, Antalffy is a 3-star analyst with an average return of 2.8% and a 42.9% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Treace Medical Concepts, and Inspire Medical Systems.
Vericel has an analyst consensus of Strong Buy, with a price target consensus of $44.75, a 59.7% upside from current levels. In a report issued on May 4, BTIG also maintained a Buy rating on the stock with a $45.00 price target.
Based on Vericel’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $36.07 million and GAAP net loss of $7.09 million. In comparison, last year the company earned revenue of $34.57 million and had a GAAP net loss of $3.29 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
Read More on VCEL:
- SVB Securities Thinks Immunic’s Stock is Going to Recover
- Why Coinbase Remains Attractive from a Long-Term Perspective
- ChemoCentryx (CCXI) Gets a Buy Rating from SVB Securities
- Zentalis Pharmaceuticals (ZNTL) Receives a Buy from SVB Securities
- SVB Securities Keeps a Buy Rating on Kura Oncology (KURA)